Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Rigosertib |
INN | rigosertib |
Description | Rigosertib is an N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine in which the double bond has E-configuration. It is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM and exhibits anti-cancer properties. It has a role as a microtubule-destabilising agent, an EC 2.7.11.21 (polo kinase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a conjugate acid of a rigosertib(1-). |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1 |
PDB | — |
CAS-ID | 592542-59-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1241855 |
ChEBI ID | — |
PubChem CID | 6918736 |
DrugBank | DB12146 |
UNII ID | 67DOW7F9GL (ChemIDplus, GSRS) |